You are here

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Last updated on November 9, 2019

FOR MORE INFORMATION
Study Location
Spain Rehabilitation Center
Birmingham, Alabama, 35233 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Ischemic Stroke
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-85 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of ischemic stroke with an onset within 72 hours prior to start of study
agent administration, male or female.

- Supratentorial ischemic stroke involving the cortex documented by neurological exam
and confirmed by MRI.

- Stroke involving upper extremity.

- Subjects who received thrombolytic therapy may be enrolled and the use of
antiplatelet is acceptable.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Any other severe acute or chronic medical or psychiatric condition besides the
stroke.

- Women of child bearing potential.

- Uncontrolled hypertension.

NCT01208233
Pfizer
Terminated
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Descriptive Information
Brief Title  ICMJE Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Official Title  ICMJE A Phase 2 Multicenter, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of Pf-03049423 In Subjects With Ischemic Stroke
Brief SummaryThe purpose of this study is to evaluate the safety and tolerability of PF-03049423 following multiple dose administration to subjects with ischemic stroke. The study will also evaluate the efficacy of PF-03049423, relative to placebo, in subjects with ischemic stroke following 90 days of therapy. The study will also explore the relationship between PF-03049423 concentration and blood pressure.
Detailed DescriptionThe interim analysis for the POC study A9541004 demonstrated futility, and the study was stopped on the 6th of November 2013. There were no signals of serious safety concern.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Ischemic Stroke
Intervention  ICMJE
  • Drug: PF-03049423
    1 mg of PF-03049423 daily for 90 days
  • Drug: PF-03049423
    3 mg of PF-03049423 daily for 90 days
  • Drug: PF-03049423
    6 mg of PF-03049423 daily for 90 days
  • Other: Placebo
    Placebo of PF-03049423 daily for 90 days
Study Arms  ICMJE
  • Experimental: 1 mg PF-03049423
    Intervention: Drug: PF-03049423
  • Experimental: 3 mg of PF-03049423
    Intervention: Drug: PF-03049423
  • Experimental: 6 mg of PF-03049423
    Intervention: Drug: PF-03049423
  • Placebo Comparator: Placebo
    Intervention: Other: Placebo
Publications *Di Cesare F, Mancuso J, Woodward P, Bednar MM, Loudon PT; A9541004 Stroke Study Group. Phosphodiesterase-5 Inhibitor PF-03049423 Effect on Stroke Recovery: A Double-Blind, Placebo-Controlled Randomized Clinical Trial. J Stroke Cerebrovasc Dis. 2016 Mar;25(3):642-9. doi: 10.1016/j.jstrokecerebrovasdis.2015.11.026. Epub 2015 Dec 28.


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: January 30, 2014)
181
Original Estimated Enrollment  ICMJE
 (submitted: September 22, 2010)
240
Actual Study Completion Date  ICMJE December 2013
Actual Primary Completion DateDecember 2013   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Diagnosis of ischemic stroke with an onset within 72 hours prior to start of study agent administration, male or female.
  • Supratentorial ischemic stroke involving the cortex documented by neurological exam and confirmed by MRI.
  • Stroke involving upper extremity.
  • Subjects who received thrombolytic therapy may be enrolled and the use of antiplatelet is acceptable.

Exclusion Criteria:

  • Any other severe acute or chronic medical or psychiatric condition besides the stroke.
  • Women of child bearing potential.
  • Uncontrolled hypertension.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 85 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Bulgaria,   Canada,   Czech Republic,   France,   Germany,   Hungary,   India,   Korea, Republic of,   Taiwan,   United States
Removed Location CountriesMexico
 
Administrative Information
NCT Number  ICMJE NCT01208233
Other Study ID Numbers  ICMJE A9541004
2010-021414-32 ( EudraCT Number )
Has Data Monitoring CommitteeYes
U.S. FDA-regulated ProductNot Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible PartyPfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateJanuary 2016

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now